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Abstract
Objective: Troublesome hot flushes and night sweats (HFNS) are experienced by
many women after treatment for breast cancer, impacting significantly on sleep and
quality of life. Cognitive behavioural therapy (CBT) is known to be effective for the
alleviation of HFNS. However, it is not known if it can effectively be delivered by
specialist nurses. We investigated whether group CBT, delivered by breast care
nurses (BCNs), can reduce the impact of HFNS.
Methods: We recruited women with primary breast cancer following primary treat-
ment with seven or more HFNS/week (including 4/10 or above on the HFNS prob-
lem rating scale), from six UK hospitals to an open, randomised, phase
3 effectiveness trial. Participants were randomised to Group CBT or usual care (UC).
The primary endpoint was HFNS problem rating at 26 weeks after randomisation.
Secondary outcomes included sleep, depression, anxiety and quality of life.
Results: Between 2017 and 2018, 130 participants were recruited (CBT:63, control:67).
We found a 46% (6.9-3.7) reduction in the mean HFNS problem rating score from
randomisation to 26 weeks in the CBT arm and a 15% (6.5-5.5) reduction in the UC arm
(adjusted mean difference −1.96, CI −3.68 to −0.23, P = .039). Secondary outcomes,
including frequency of HFNS, sleep, anxiety and depression all improved significantly.
Conclusion: Our results suggest that specialist nurses can be trained to deliver CBT
effectively to alleviate troublesome menopausal hot flushes in women following
breast cancer in the NHS setting.
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1 | INTRODUCTION
Hot flushes and night sweats (HFNS) may be experienced by up to
85% of women after breast cancer,1 having a significant impact on
sleep, quality of life and with social consequences on employment and
personal relationships.2-4 HFNS tend to be worse in women who have
been treated for breast cancer, largely because many breast cancer
treatments are aimed at suppressing or opposing oestrogen, with
HFNS being the natural consequence. Furthermore, oestrogen
replacement is contraindicated in women with breast cancer.
The use of serotonin and norepinephrine reuptake inhibitors
(SSRI and SNRIs), such as venlafaxine and citalopram, have been
favoured as the best available treatment for hot flushes after breast
cancer.5 These show moderate reductions in HFNS frequency but
have little effect on quality of life measures; furthermore, they may be
associated with unpleasant side effects, such as anorgasmia, anxiety,
insomnia, restlessness and headaches, as well as having potential
interactions with other medication, such as tamoxifen.5,6 Furthermore,
many women prefer to employ non-medical alternatives following
their breast cancer treatment.7 There are currently no consistent stan-
dard care pathways for HFNS in UK practice and few women are
offered any effective management for this problem.8
There is evidence that cognitive behavioural therapy (CBT) is
effective for the alleviation of HFNS in women. CBT for menopausal
symptoms was developed by Hunter and colleagues9 and has been
evaluated in several randomised controlled trials.10-13 The interven-
tion draws on Hunter and Mann's14 theoretical model of HFNS, based
on symptom perception, self-regulation and cognitive behavioural the-
ories to explain women's cognitive appraisal and behavioural reactions
to symptoms. This model has been tested in a variety of settings and
shows that women's beliefs drive the way that women experience
HFNS and that their perception of HFNS as problematic can be
altered by changes in beliefs and behaviours15-17 (Figure 1). The com-
bination of cognitive and behavioural changes can bring about reduc-
tions in the extent to which women view HFNS as problematic and
interfering with their lives, as well as improvements in mood, sleep
and quality of life.
Health professional-led group sessions provide a cost-effective
solution and were positively viewed in the previous MENOS1 trial.11
Beyond HFNS, benefits of CBT, such as improvements in mood and
quality of life, were found to be more pronounced for group CBT than
with self-help CBT in a trial with well women.10 While it has been
demonstrated that this is an effective intervention to help alleviate
HFNS in women after breast cancer11,12 there are still large numbers
of women suffering who do not have access to group CBT.8
There is an increasing awareness that new evidence is not always
routinely incorporated into practice.18 In order to make this interven-
tion available to women, it was hypothesised that this was most likely
to happen if implemented by those health professionals who already
provide interventions to support women throughout their breast can-
cer experience. Most women with breast cancer will see a breast care
nurse (BCN), whose role it is to support women to cope with the con-
sequences of their treatment. The delivery of BCN-led group CBT ses-

















F IGURE 1 A typical cognitive
behavioural therapy vicious cycle of
thoughts, feelings and behaviours when
women have problematic hot flushes
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is some evidence that nurses can effectively deliver CBT for cancer
patients;19 however, training nurses to deliver CBT for menopausal
hot flushes according to the MENOS protocol has not yet been evalu-
ated. We designed the MENOS 4 study to investigate whether breast
care nurses can be trained to deliver CBT in an NHS context to effec-
tively manage HFNS in women who have had breast cancer.
2 | METHODS
2.1 | Study design and participants
The MENOS4 study was a multi-centre phase III randomised con-
trolled trial of BCN-delivered group CBT vs usual care (see trial proto-
col20). The primary aim was to evaluate the effectiveness of BCN-led
group CBT on reducing the impact of HFNS in women with breast
cancer 26 weeks after randomisation. Secondary aims included:
(a) impact on HFNS 9 weeks after randomisation; (b) frequency of
HFNS at 9 and 26 weeks; (c) the level of fidelity of CBT when deliv-
ered by BCNs; (d) the effect of group CBT on quality of life (QoL) and
other symptoms, for example, sleep, anxiety (e) the effect on women's
hot flush beliefs and behaviours and (f) an estimate of the cost-
effectiveness.
Recruitment took place in hospitals throughout England and
Wales. We included females 16 years and older, with primary breast
cancer or DCIS, who had completed primary treatment, experiencing
seven or more HFNS/week, with an overall rating of 4/10 or above
on the Hot Flush Problem Rating scale21 and the desire and ability to
attend group sessions. Exclusion criteria were metastatic disease and
male. All women provided written informed consent before enrolment
and randomisation. Approval was gained from a UK Research Ethics
Committee (16/SC/0364), and NHS R&D departments at participating
sites. The study was sponsored by the University of Southampton and
coordinated by the Southampton Clinical Trials Unit (SCTU). The trial
is registered with International Standard Randomized Controlled Trial
Number 12824632.
2.2 | Procedures
Potential participants were identified and recruited via: (a) identification
at breast cancer follow-up clinics; (b) letter of invitation from research
nurses to potential participants; (c) participant identification centres
where potential participants could be referred to a research site;
(d) leaflets and posters in clinics and local health and wellbeing events;
(e) social media promotion strategies including through Breast Cancer
Now, Breast Cancer Haven and Twitter.
2.3 | Randomisation
Once 12 to 16 eligible participants were recruited at each site, individ-
ual randomisation was conducted by an independent statistician,
allocating participants in a 1:1 ratio, stratified by site, with fixed block
size. Each site aimed to run two sequential groups of the intervention
with 6 to 8 women per group.
2.4 | Intervention arm—CBT
The BCNs delivering the intervention were selected by sites and
trained by a clinical psychologist (MSH) over 2 days, using the
training manual22 to deliver the CBT intervention. The manual con-
tains detailed session content; presentation slides and handouts.
For full training details on training and a description of the CBT,
see the protocol paper.20 Following training, the BCNs received
ongoing supervision of their delivery of group CBT from the trainer
by email or telephone as required. Intervention arm participants
attended weekly group CBT sessions, lasting 90 minutes each, for
6 weeks, following the structured manual,22 which included a
psycho-education and the cognitive behavioural model; stress
management; paced breathing; cognitive and behavioural strategies
to improve wellbeing and for managing hot flushes, night sweats
and sleep; and maintaining changes. A typical CBT vicious cycle of
thoughts, feelings and behaviours that women with troublesome
symptoms report is shown in Figure 1. The CBT, targeting the cog-
nitive and behavioural elements, is described in full in the manual,
which has PowerPoint slides, homework sheets and a paced
breathing relaxation CD.22
2.5 | Control arm
Usual care (UC) was standard NHS care at the site. Each site used
their normal approach, which differed between sites, since there is no
current UK standard of care. Women were generally given ad hoc
advice about HFNS, typically, only if they raised the issue. For ethical
reasons, participants in the usual care arm were offered a version of
self-help CBT after the final assessment at week 26.
2.6 | Outcome measures
At baseline, demographic and clinical information were recorded.
At both baseline, 9 weeks and 26 weeks after randomisation, we
recorded the number of HFNS and bother related to HFNS using a
3-day diary card, hot flushes (HFNS Rating scale & HFNS Belief
and Behaviour Scale), depression (patient health questionnaire
[PHQ], general anxiety disorder (GAD-7), sleep (Pittsburgh Sleep
Quality Index [PSQI]), impact of hot flushes on daily activities and
overall QoL (Hot Flash Related Daily Interference Scale
[HFRDIS])23 and quality of life (EQ-5D-5 L - also collected on
weeks 3 and 6 while on intervention). See protocol paper for full
description.20
The primary outcome measure was HFNS Problem Rating24
taken at 26 weeks after randomisation. This measure has been used
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in clinical trials and predicts QoL and help-seeking to a greater
extent than HFNS frequency and is recommended as an appropri-
ate outcome measure in trials of HFNS treatments.24,25 Problem
rating and severity tend to be associated with each other—neither
are strongly associated with frequency of HFNS.21,24 HFNS prob-
lem rating has good internal consistency (Cronbach α = 0·9) and
test-retest reliability (r = 0·8)24 and has been used successfully in
previous MENOS studies.
Secondary outcomes included HFNS problem rating at 9 weeks,
and HFNS frequency, beliefs about HFNS, the hot flash related daily
interference scale (HFRDIS)26 quality of life, sleep, anxiety and
depression measures at 9 and 26 weeks after randomisation. The
original intention was to include FACT-ES to explore quality of life
but this was withdrawn later to shorten the questionnaire and
improve response rate. The Short Form Hot Flush Beliefs and Behav-
iours Scale (HFBBS) was used to collect information about beliefs
and behaviours about hot flushes.27,28 Data were collected for health
economic analysis using EQ5D29 and process evaluation based on
Normalisation Process Theory.30 These data will be reported else-
where. Serious adverse events were notified to SCTU at the 9-week
questionnaire time-point and followed up accordingly with the
research nurse and the participants' GP.
2.7 | Adherence
Patient adherence to group CBT was measured by the number of ses-
sions attended and the number of times that a participant reported
practising relaxation/paced breathing each week. Where participants
missed a session, the BCN covered the session by telephone (up to
30 minutes).
2.8 | Fidelity
All group sessions were audio recorded (with consent), and 17% were
randomly selected, ensuring two sessions per site were selected. An
independent psychologist, not involved in the training, rated the BCNs
for their fidelity and adherence to the manual.
2.9 | Sample size
A difference of two points or more in the HFNS Problem Rating Scale
is regarded as clinically relevant.11 To detect a two-point difference
(SD 2.4; standardised effect size 0.8), in mean HFNS problem rating
between arms, 90% power requires 64 participants in total, assuming
a two-sided significance level of 0.05. Allowing for inflation factor of
1.49 (intraclass correlation 0.07; 8 participants per group),31 to adjust
for expected clustering within groups, gave a minimum sample size of
96, increasing to 120 to allow for 20% loss to follow-up and for each
site to run two groups.
2.10 | Statistical analysis
The difference in HFNS Problem Rating Scale between the two arms
was tested using a linear mixed model, utilising fixed and random
effects. The regression model compared HFNS problem rating between
arms at follow-up, adjusting for baseline HFNS problem rating score,
cohort and stratification factor (site). Greater precision of estimates
was expected within therapy groups (clustering effect), so the therapist
was fitted as a random effect for the partially nested data. Secondary
outcomes at follow-up were analysed in a similar way. For secondary
outcome models where residuals were not normally distributed and no
sensible transformation could be utilised, quantile regression adjusting
for baseline score, cohort and site was used. Repeated measures ana-
lyses were utilised to allow simultaneous modelling of the three out-
come time points. Analyses were based on a modified intention-to-
treat population (ie, excluding participants who contribute fewer than
two items on the outcome measure). All analyses were conducted
according to a pre-specified analysis plan using SAS v9.4 and approved
by the trial team before completion of data collection. P values less
than 0·05 were regarded as significant for all analyses.
3 | RESULTS
Between February 2017 and January 2018, 130 women were rec-
ruited from six UK hospitals. Sixty-three women were allocated to
group CBT and 67 to UC (see Figure S1). Three women (CBT:2 and
UC:1) withdrew, resulting in study data available for 127 (CBT:61,
UC:66). The baseline characteristics were well balanced between
groups (Table 1). At the start of the trial, women were suffering a
median of 58 (Inter Quartile Range [IQR] 35-84) flushes per week
(CBT group) and 63 (IQR 28-91) (UC group) and a mean problem rating
of 6.9 (SD 1.73) out of 10 (CBT group) and 6.5 (SD 2.13) (UC group).
3.1 | Treatment adherence
The group sessions included 5 to 9 participants (except one group of
3). Participant adherence to treatment was good; 45 (73.8%) of 61 par-
ticipants who received CBT, attended at least four sessions. Of 68%
(43/63) who answered the question, the majority practised paced
breathing daily (60%), 21% 3 to 4 times a week, 14% 5 to 6 times, and
5% only 1 to 2 times. Of 67% (42/63) who answered the question,
17% used the relaxation CD daily, 12% 5 to 6 times/week, 36% 3 to
4 times/week, 29% 1 to 2 times/week and 6% not at all.
3.2 | HFNS problem rating
For the primary endpoint—HFNS problem rating score at 26 weeks—
we found a statistically significant difference between groups
(P = .039), equivalent to a 46% (6.9-3.7) reduction in the HFNS
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problem rating score in the CBT arm and a 15% (6.5-5.5) reduction in
the UC arm (Table 2, Figure 2). We conducted pre-specified sensitivity
analyses on the primary outcome at 26-weeks for group size and
those women who only received 4 of the 6 sessions. The effect held
for both analyses (Table 2).
3.3 | HFNS frequency
We found a significant difference between groups in HFNS fre-
quency at 26 weeks, with a 28% (58-42) reduction in HFNS
incidence in the CBT group compared to an 11% (63-56) reduction in
the UC group (P = .010). Similar results were found at 9 weeks
(P = .017) (Table 3).
3.4 | Hot flash related daily interference scale
(HFRDIS)
There was a significant difference in the Hot Flash Related Daily Inter-
ference Scale (HFRDIS) between groups at 26 weeks (P < .0001) and
9 weeks (P < .0001) (Table 3).
TABLE 1 Demographics and clinical details
CBT (n = 61) Usual care (n = 66)
Site
Luton and Dunstable 12 (19.7%) 11 (16.7%)
Royal Glamorgan Cardiff 10 (16.4%) 11 (16.7%)
Walsall Manor Hospital 5 (8.2%) 6 (9.1%)
Queen Alexandra Portsmouth 14 (23.0%) 15 (22.7%)
York Teaching Hospital 7 (11.5%) 8 (12.1%)
Yeovil District Hospital 13 (21.3%) 15 (22.7%)
Age at baseline assessment (years; mean [SD]) 53.5 (9.78) 55.2 (10.19)
Mean BMI (kg/m2; SD) 28.5 (4.61) 28.1 (4.94)
Ethnicity White 58 (96.7%) 62 (95.4%)
Married/living with partner 43 (72.9%) 54 (84.4%)
Educated 16+ years of age 38 (64.4%) 30 (46.2%)
Employed 34 (56.7%) 40 (60.6%)
Current smoker 5 (8.5%) 5 (7.6%)
Exercise
Once a week or less 27 (45.0%) 22 (33.3%)
More than once a week 33 (55.1%) 44 (66.7%)
Alcohol consumption (units per week)
>7 55 (91.7%) 56 (84.8%)
7+ 5 (8.4%) 10 (15.1%)
Distance participant lives from the treatment centre (miles;
median [IQR])
6.0 (4.0-10.0) 6.0 (3.0-12.0)
Treatment history
Chemotherapy 38 (62.3%) 33 (50.0%)
Radiotherapy 57 (93.4%) 56 (84.8%)
Herceptin 9 (15.8%) 6 (9.5%)
Hysterectomy 14 (23.0%) 9 (13.6%)
Bilateral oophorectomy 9 (15.5%) 6 (9.1%)
Time since last period (years; median [IQR]) 4.0 (1.0-8.0) 4.0 (1.0–8.0)
Taking endocrine treatment at baseline 55 (90.1%) 65 (98.4%)
Taking a prescribed drug for HFNS at baseline 18 (34.0%) 18 (30.5%)
Baseline HFNS problem rating (mean [SD]) 6.9 (1.73) 6.5 (2.13)
Baseline HFNS frequency (per week; mean [SD]) 62.3 (32.21) 67.1 (46.89)
Abbreviations: CBT, cognitive behavioural therapy; HFNS, hot flushes and night sweats; IQR, Inter Quartile Range.
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3.5 | Sleep, anxiety and depression
There was significant improvement in sleep quality at both 26 weeks
(P < .0001) and 9 weeks (P < .0001) (Table 3). Anxiety and depression
also both significantly improved at both 9 and 26 weeks (Table 3).
3.6 | Beliefs and behaviours about HFNS
Negative beliefs about HFNS improved for all subscales in the CBT
group, as did positive coping behaviour; there was a significant improve-
ment between group difference at both 9 and 26 weeks. (Table 3).
3.7 | Fidelity
CBT was delivered according to the treatment manual, with an aver-
age of 94% adherence. The majority (10/12) of BCNs adhered to
>90% of the CBT topics, (range 75%-100%). The most frequent ses-
sion aim not delivered was the practising of paced breathing; how-
ever, a review of relaxation and paced breathing was always
conducted.
Eleven BCNs underwent the training (all female, aged
45-48 years). Four had prior experience of delivering group sessions
and eight had received advanced communication skills training. Three
had received training in counselling, only one had experience or
TABLE 2 Hot flush and night sweats problem-rating scores
CBT mean (SD) Usual care: mean (SD)
CBT vs usual care mean difference
(95% CI; P value)
HFNS
Baseline 6.9 (1.73) 6.5 (2.13)
9 weeks 4.1 (2.01) 5.5 (2.61) −1.83 (−2.53 to −1.12; <.0001)
26 weeks 3.7 (2.16) 5.5 (2.45) −1.96 (−3.68 to −0.23; .039)
HFNS (excluding patients with <4 CBT sessions/
telephone calls)
Baseline 6.7 (1.73) 6.5 (2.13)
9 weeks 3.7 (1.88) 5.5 (2.61) −2.11 (−3.02 to −1.20; .0018)
26 weeks 3.3 (1.86) 5.5 (2.45) −2.38 (−3.21 to −1.55; <.0001)
HFNS (excluding one cohort of two patients)
Baseline 6.9 (1.72) 6.5 (2.18)
9 weeks 4.1 (2.02) 5.5 (2.69) −1.78 (−2.52 to −1.04; <.0001)
26 weeks 3.7 (2.16) 5.5 (2.49) −1.89 (−2.75 to −1.03; <.0001)
Abbreviations: CBT, cognitive behavioural therapy; HFNS, hot flushes and night sweats; IQR, Inter Quartile Range.
F IGURE 2 Hot flushes and night
sweats problem rating score vs time
from randomisation (Usual care vs
cognitive behavioural therapy)
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TABLE 3 Effect of treatment on hot flushes and night sweats and secondary measures
Mean (SD)
Adjusted mean diff 95%CI; P valueCBT Usual care
HFRDIS
Baseline 57.8 (21.20) 51.8 (23.29)
9 weeks 30.9 (22.79) 45.1 (24.90) −19.55 −27.20 to −11.91; <.0001
26 weeks 29.6 (25.23) 46.1 (24.83) −21.36 −29.79 to −12.94; <.0001
Depression (PHQ-9)
Baseline 18.9 (5.77) 17.7 (6.06)
9 weeks 15.9 (5.37) 17.2 (5.51) −2.47 −4.20 to −0.74; .006
Sleep quality (Pittsburgh)
Baseline 2.9 (0.83) 2.9 (0.74)
26 weeks 2.3 (0.78) 2.9 (0.68) −0.57 −0.81 to −0.33; <.0001
Median (IQR)
Adjusted median diff 95% CI; P valueCBT Usual care
Total HFNS frequency
Baseline 58.0 (35.0-84.0) 63.0 (28.0-91.0)
9 weeks 38.5 (16.0-73.0) 49.0 (22.0-80.5) −13.41 −24.38 to −2.44; .017
26 weeks 42.0 (17.0-63.0) 56.0 (28.0-77.0) −20.22 −34.46 to −4.93; .010
Anxiety (GAD-7)
Baseline 13.0 (10.5-16.0) 11.0 (8.0-15.0)
9 weeks 10.0 (7.0-14.0) 12.0 (9.0-15.1) −1.54 −3.01 to −0.07; .041
26 weeks 11.0 (7.0-14.0) 12.0 (9.0-17.0) −2.14 −3.61 to −0.66; .005
Sleep quality (Pittsburgh)
Baseline 3.0 (2.0-3.5) 3.0 (2.0-3.0)
9 weeks 2.0 (2.0-3.0) 3.0 (3.0-3.0) −0.67 −0.94 to −0.39; <.0001
Depression (PHQ-9)
Baseline 18.0 (15.0-22.0) 16.0 (13.0-20.0)
26 weeks 15.0 (12.0-18.0) 17.0 (12.5-20.5) −2.86 −4.73 to −0.98; .003
Mean (SD)
Adjusted mean diff 95% CI; P valueCBT Usual care
HFBBS (subscale 1)
Baseline 2.7 (1.66) 2.6 (1.48)
9 weeks 1.7 (1.44) 2.4 (1.50) −0.84 −1.31 to −0.37; .0006
26 weeks 1.7 (1.46) 2.2 (1.62) −0.71 −1.09 to −0.33; .0004
HFBBS (subscale 2)
Baseline 2.8 (1.14) 2.7 (1.15)
9 weeks 1.8 (1.43) 2.6 (1.02) −0.96 −1.62 to −0.29; .013
26 weeks 1.7 (1.42) 2.5 (1.09) −0.87 −1.32 to −0.41; .0003
HFBBS (subscale 3)
Baseline 2.8 (1.23) 2.3 (1.08)
9 weeks 1.4 (0.93) 2.2 (1.28) −1.01 −1.38 to −0.64; <.0001
26 weeks 1.3 (1.23) 2.0 (1.22) −0.96 −1.38 to −0.54; <.0001
HFBBS (subscale 5)
Baseline 1.9 (1.43) 1.5 (1.43)
26 weeks 1.3 (1.48) 1.5 (1.41) −0.63 −1.88 to 0.61; .159
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training in CBT. Nine BCNs completed pre- and post-questionnaires.
The average confidence for skills to run group CBT (scale 1-10) was
5.3 before and 7.7 after training. Their views of how effective training
would be were, on average, 6.7 pre- and 8.2 post-training. Their aver-
age confidence in using the CBT model with participants for stress
and hot flushes increased from 5.2 before to 8.1.
4 | DISCUSSION
These findings support previous studies,11,12 which show that group
CBT for HFNS is effective in helping women who have had breast
cancer to manage troublesome HFNS.
4.1 | Clinical implications
For the first time, we provide evidence that this intervention can be
delivered effectively by nurses in the NHS setting; previous trials have
been led by a clinical psychologist. This intervention of group CBT,
delivered by trained breast care nurses, was effective in reducing not
only the extent to which HFNS was regarded as a problem by women,
but other benefits included a reduction in the frequency of HFNS,
improved sleep, reduced anxiety and depression and reduced impact
on everyday life. Furthermore, the benefit immediately following the
group intervention at 9 weeks was sustained at 26 weeks. Sensitivity
analyses suggested that these effects were neither influenced by the
cohort group, nor the individual delivering the intervention, which
suggests that this intervention would be replicable across the NHS.
The programme itself is easily transferable because it is manualised,22
and adherence to the manual was high. An implementation strategy
needs to be developed and this intervention could potentially be
delivered as part of a survivorship programme.18
In contrast to serotonin and norepinephrine reuptake inhibitors,
CBT resulted in statistically significant and lasting improvements in
frequency and problem-rating of HFNS, as well as improved sleep,
anxiety and depression.
4.2 | Study limitations
This study used a different quality of life measure to the
MENOS1 trial,11 so direct comparisons could not be made. Nor
did we collect potential adverse psychological effects from the
intervention.32 Although we did not conduct a formal mediation
analysis, we demonstrated changes in HFNS beliefs and behav-
iours, that is, cognitive appraisal and behavioural reactions—
factors that have been found to mediate improvements in HFNS
following this CBT protocol.16,17 These changes also support
Hunter and Mann's14 cognitive model of HFNS. The results add
to the evidence that CBT is a safe and effective intervention with
specific benefits to HFNS compared to non-medical alternatives,
such as mindfulness, yoga, acupuncture.33
Further research might explore the broader implementation of
the CBT intervention; for example, “training the trainer,” online learn-
ing, congress workshops, etc, that were not covered in this study.
5 | CONCLUSIONS
Our findings suggest that CBT is an important alternative to
medication for women with troublesome hot flushes and night
sweats following breast cancer treatment, and that this interven-
tion can be delivered in practice by trained breast care nurses in
the NHS, with significant benefit to patients to improve their
health.
ACKNOWLEDGEMENTS
Breast Cancer Now commissioned MENOS4(2015CR_004). The
commissioning board commented on study design, but no further part
in management or analysis. Recruitment was supported by the
research nurses and staff within the NIHR Clinical Research Network
Cancer in England and Welsh equivalent. We thank Melanie Smith for
conducting the fidelity assessment. We thank J. Haviland, L. Yao and
P. Khambaita for advising on the original proposal and T. Rose,
A. Galanopolou, J. Abab and E. Kirkpatrick for their contribution.
TABLE 3 (Continued)
Median (IQR)
Adjusted median diff 95% CI; P valueCBT Usual care
HFBBS (subscale 4)
Baseline 3.3 (2.3-3.7) 3.0 (2.7-4.0)
9 weeks 4.0 (3.3-4.3) 3.3 (2.3-4.0) 0.71 0.24 to 1.18; 0.004
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HFBBS (subscale 5)
Baseline 2.0 (0.7-3.0) 1.2 (0.3-2.7)
9 weeks 1.0 (0.0-2.0) 1.0 (0.3-2.0) −0.49 −1.07 to 0.08; 0.093
Abbreviations: CBT, cognitive behavioural therapy; HFBBS, Hot Flush Beliefs and Behaviours Scale; HFNS, hot flushes and night sweats; HFRDIS, Hot
Flush Related Daily Interference Scale; IQR, Inter Quartile Range; PHQ, patient health questionnaire.
FENLON ET AL. 1521
Finally, we thank the principal investigators and their colleagues for
recruitment and treatment of patients.
CONFLICT OF INTEREST
M.S.H. developed the CBT programme and co-authored the CBT
manual, but has no other financial support from pharmaceutical or pri-
vate practice. D.F.: honorarium from Roche. All others have no con-
flicts of interest.
DATA AVAILABILITY STATEMENT
Data supporting the findings of this study will be made available on
request from the corresponding author for approved data sharing
requests. Anonymous data will be available for request from three
months after publication, to researchers who provide a completed
Data Sharing request form for the purpose of an approved proposal
and if appropriate, signed a Data Sharing Agreement. The data are not




1. Gupta P, Sturdee D, Palin S, et al. Menopausal symptoms in women
treated for breast cancer: the prevalence and severity of symptoms
and their perceived effects on quality of life. Climacteric. 2006;9:
49-58.
2. Fenlon DR, Rogers AE. The experience of hot flushes after breast can-
cer. Cancer Nurs. 2007;30(4):E19-E26.
3. Fenlon DR, Corner JL, Haviland J. Menopausal hot flushes after breast
cancer. Eur J Cancer Care. 2009;18(2):140-148.
4. Hunter MS, Grunfeld EA, Mittal S, et al. Menopausal symptoms in
women with breast cancer: prevalence and treatment preferences.
Psychooncology. 2004;13:769-778.
5. Szabo RA, Marino JL, Hickey M. Managing menopausal symptoms
after cancer. Climacteric. 2019;22(6):572-578. https://doi.org/10.
1080/13697137.2019.1646718.
6. Santarsieri D, Schwartz TL. Antidepressant efficacy and side-effect
burden: a quick guide for clinicians. Drugs Context. 2015;4:1-12.
7. Reece JC, Chan YF, Herbert J, Gralow J, Fann JR. Course of depres-
sion, mental health service utilization and treatment preferences in
women receiving chemotherapy for breast cancer. Gen Hosp Psychia-
try. 2013;35(4):376-381.
8. Fenlon D, Morgan A, Khambaita P, et al. Management of hot flushes
in UK breast cancer patients: clinician and patient perspectives.
J Psychosom Obstet Gynecol. 2017;38(4):276-283.
9. Hunter MS. Cognitive behavioural interventions for the treatment
of menopausal symptoms. Expert Rev Obstet Gynaeco. 2012;4:
321-326.
10. Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of
group and self-help cognitive behaviour therapy to reduce problem-
atic menopausal hot flushes and night sweats (MENOS 2): a random-
ized controlled trial. Menopause: J North Am Menopause Soc. 2012;19
(7):749-759. https://doi.org/10.1097/gme.0b013e31823fe835.
11. Mann E, Smith MJ, Hellier J, Hamed H, Grunfeld B, Hunter MS. Effi-
cacy of a cognitive behavioural intervention to treat menopausal
symptoms following breast cancer treatment (MENOS 1): a
randomised controlled trial. Lancet Oncol. 2012;13(3):309-318.
12. Duijts SFA, van Beurden M, Oldenburg HSA, et al. Efficacy of cogni-
tive behavioral therapy and physical exercise in alleviating treatment-
induced menopausal symptoms in patients with breast cancer: results
of a randomized controlled multicenter trial. J Clin Oncol. 2012;30
(33):4124-4133.
13. Atema V, van Leeuwen M, Kieffer JM, et al. Efficacy of internet-based
cognitive behavioral therapy for treatment-induced menopausal
symptoms in breast cancer survivors: results of a randomized con-
trolled trial. J Clin Oncol. 2019;37:809-822. https://doi.org/10.1200/
JCO.18.00655.
14. Hunter MS, Mann E. A cognitive model of menopausal hot flushes
and night sweats. J Psychosom Res. 2010;69(5):491-501.
15. Hunter MS, Chilcot J. Testing a cognitive model of menopausal hot
flushes and night sweats. J Psychosom Res. 2013;74(4):307-312.
16. Chilcot J, Norton S, Hunter MS. Cognitive behaviour therapy for
menopausal symptoms following breast cancer treatment: who bene-
fits and how does it work? Maturitas. 2014;78(1):56-61.
17. Norton S, Chilcot J, Hunter MS. Cognitive behaviour therapy for
menopausal symptoms (hot flushes and night sweats): moderators
and mediators of treatment effects. Menopause. 2014;21(6):574-578.
18. Eccles M, Grimshaw J, Foy R. Disseminating and implementing
evidence-based practice. Clinical governance in primary care. London:
CRC Press; 2018:75-88.
19. Espie CA, Fleming L, Cassidy J, et al. Randomized controlled clinical
effectiveness trial of cognitive behavior therapy compared with treat-
ment as usual for persistent insomnia in patients with cancer. J Clin
Oncol. 2008;26(28):4651-4658.
20. Fenlon D, Nuttall J, May C, et al. MENOS4 trial: a multicentre
randomised controlled trial (RCT) of a breast care nurse delivered
cognitive behavioural therapy (CBT) intervention to reduce the
impact of hot flushes in women with breast cancer: study protocol.
BMC Womens Health. 2018;18(1):63.
21. Hunter MS, Nuttall J, Fenlon D. A comparison of three outcome mea-
sures of the impact of vasomotor symptoms on women's lives. Cli-
macteric. 2019;22(4):319-423.
22. Hunter M, Smith M. Managing hot flushes with group cognitive behav-
iour therapy: an evidence based treatment manual for health profes-
sionals. New York, NY: Routledge; 2014.
23. Carpenter JS, Rand KL. Modeling the hot flash experience in breast
cancer survivors. Menopause. 2018;15(3):469-475.
24. Hunter MS, Liao KLM. A psychological analysis of menopausal hot
flushes. Br J Clin Psychol. 1995;34:589-599.
25. Rand KL, Otte JL, Flockhart D, et al. Modeling hot flushes and quality
of life in breast cancer survivors. Climacteric. 2011;14(1):171-180.
26. Carpenter JS. The hot flash related daily interference scale: a tool for
assessing the impact of hot flashes on quality of life following breast
cancer. J Pain Symptom Manag. 2001;22(6):979-989.
27. Hunter MS, Ayers B, Smith M. 2011 the hot flush behavior scale: a
measure of behavioral reactions to menopausal hot flushes and night
sweats. Menopause. 2011;18(11):1178-1183.
28. Rendall MJ, Simmons LM, Hunter MS. The hot flush beliefs scale: a tool
for assessing thoughts and beliefs associated with experience of meno-
pausal hot flushes and night sweats.Maturitas. 2008;60:158-169.
29. Chisholm D, Knapp MRJ, Knudsen HC, et al. Client socio-
demographic and service receipt inventory - European version: devel-
opment of an instrument for international research. Br J Psychiatry.
2000;177(39):s28-s33. https://doi.org/10.1192/bjp.177.39.s28.
30. Murray E, Treweek S, Pope C, et al. Normalisation process theory: a
framework for developing, evaluating and implementing complex
interventions. BMC Med. 2010;8(1):63.
31. Wampold BE, Brown GS. Estimating variability in outcomes attribut-
able to therapists: a naturalistic study of outcomes in managed care.
J Consult Clin Psychol. 2005;73(5):914-923.
32. Rozental A, Kottorp A, Forsström D, et al. The negative effects
questionnaire: psychometric properties of an instrument for
assessing adverse and unwanted events in psychological treatments.
Behav Cogn Psychother. 2019;47(5):559-572. https://doi.org/10.
1017/S1352465819000018.
1522 FENLON ET AL.
33. Carpenter, J., Gass, M.L., Maki, P.M., et al. Nonhormonal management
of menopause-associated vasomotor symptoms: 2015 position state-
ment of the north American Menopause Society. Menopause. 2015;
22(11):1155-1172.
SUPPORTING INFORMATION
Additional supporting information may be found online in the
Supporting Information section at the end of this article.
How to cite this article: Fenlon D, Maishman T, Day L, et al.
Effectiveness of nurse-led group CBT for hot flushes and night
sweats in women with breast cancer: Results of the MENOS4
randomised controlled trial. Psycho-Oncology. 2020;29:
1514–1523. https://doi.org/10.1002/pon.5432
FENLON ET AL. 1523
